Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.91 |
| ▸ | ESYT2 | A0FGR8 | 1/20 | 0.55 |
| ▸ | PLEKHG3 | A1L390 | 1/20 | 0.55 |
| ▸ | NBAS | A2RRP1 | 1/20 | 0.55 |
| ▸ | CNOT1 | A5YKK6 | 1/20 | 0.55 |
| ▸ | TBKBP1 | A7MCY6 | 1/20 | 0.55 |
| ▸ | MYO1G | B0I1T2 | 1/20 | 0.55 |
| ▸ | AGPS | O00116 | 1/20 | 0.55 |
| ▸ | MYO1F | O00160 | 1/20 | 0.55 |
| ▸ | SNAP23 | O00161 | 1/20 | 0.55 |
| ▸ | AP3B1 | O00203 | 1/20 | 0.55 |
| ▸ | PSMD12 | O00232 | 1/20 | 0.55 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.55 |
| ▸ | PGRMC1 | O00264 | 1/20 | 0.55 |
| ▸ | CLIC1 | O00299 | 1/20 | 0.55 |
| ▸ | CDC7 | O00311 | 1/20 | 0.55 |
| ▸ | PDHX | O00330 | 1/20 | 0.55 |
| ▸ | IPO5 | O00410 | 1/20 | 0.55 |
| ▸ | PLK4 | O00444 | 1/20 | 0.55 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20558445 | 0.95 | BTK (1.00) | BTK | |
| SCHEMBL20558453 | 0.93 | BTK (1.00) | BTKAXLTYRO3MERTK | |
| SCHEMBL27208372 | 0.92 | BTK (0.91) | BTK | |
| SCHEMBL30822331 | 0.92 | BTK (0.91) | BTK | |
| SCHEMBL20558373 | 0.89 | BTK (0.84) | BTK | |
| SCHEMBL20558369 | 0.83 | BTK (0.78) | BTKESYT2PLEKHG3NBASCNOT1 | |
| SCHEMBL20558354 | 0.83 | BTK (0.74) | BTK | |
| SCHEMBL14070193 | 0.83 | BTK (0.75) | BTKESYT2PLEKHG3NBASCNOT1 | |
| SCHEMBL14070207 | 0.81 | BTK (0.64) | BTKESYT2PLEKHG3NBASCNOT1 | |
| SCHEMBL14070246 | 0.81 | BTK (0.72) | BTKESYT2PLEKHG3NBASCNOT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-08-10 | — | — | US | claimed |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-25 | — | — | US | claimed |
| WO-2018208132-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-11-15 | — | — | WO | claimed |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-08-10 | — | — | US | disclosed |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-08-10 | — | — | US | disclosed |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-25 | — | — | US | disclosed |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-25 | — | — | US | disclosed |
| WO-2018208132-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | BTK, SYK, LCK | BTK 1/4885ESYT2 4137/4885PLEKHG3 1038/4885 |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | BTK, SYK, LCK | BTK 1/4885ESYT2 4137/4885PLEKHG3 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.